Brief: Polyphor AG Provides Update On Phase III Fortress Study Of Balixafortide In Patients With Advanced HER2 Negative Breast Cancer

Spexis AG

28/06/2021 06:02

June 28 (Reuters) - Polyphor AG  POLN.S :
    * PROVIDES UPDATE ON PHASE III FORTRESS STUDY OF
BALIXAFORTIDE IN
PATIENTS WITH ADVANCED HER2 NEGATIVE BREAST CANCER
    * CO-PRIMARY ENDPOINT OF STUDY OBJECTIVE RESPONSE RATE (ORR)
WAS
NOT MET
    * BOARD OF DIRECTORS IS UNDERGOING A STRATEGIC ASSESSMENT
REGARDING FUTURE OF COMPANY
    * STUDY CONFIRMED POSITIVE SAFETY AND TOLERABILITY PROFILE
OF
BALIXAFORTIDE IN LINE WITH PREVIOUSLY REPORTED PHASE IB STUDY
    * WILL CONTINUE TO ANALYZE DATA, REVIEW WITH EXPERTS AND
WILL
DECIDE ABOUT FUTURE OF STUDY IN MID-JULY

Source text for Eikon:  ID:nGNXbgjdkc 
Further company coverage:  POLN.S 

 ((Reuters.Briefs@thomsonreuters.com;))